154 related articles for article (PubMed ID: 30170409)
1. Hyper expression of MTBP may be an adverse signal for the survival of some malignant tumors: A data-based analysis and clinical observation.
Mao Y; Tian M; Pan B; Zhu Q; Li P; Liu H; Liu W; Dai N; Yu L; Tian Y
Medicine (Baltimore); 2018 Aug; 97(35):e12021. PubMed ID: 30170409
[TBL] [Abstract][Full Text] [Related]
2. Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.
Vlatković N; El-Fert A; Devling T; Ray-Sinha A; Gore DM; Rubbi CP; Dodson A; Jones AS; Helliwell TR; Jones TM; Boyd MT
Cancer; 2011 Jul; 117(13):2939-50. PubMed ID: 21692053
[TBL] [Abstract][Full Text] [Related]
3. MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Song Y; Zhang L; Jiang Y; Hu T; Zhang D; Qiao Q; Wang R; Wang M; Han S
Theranostics; 2019; 9(20):6019-6030. PubMed ID: 31534534
[No Abstract] [Full Text] [Related]
4. MTBP inhibits migration and metastasis of hepatocellular carcinoma.
Bi Q; Ranjan A; Fan R; Agarwal N; Welch DR; Weinman SA; Ding J; Iwakuma T
Clin Exp Metastasis; 2015 Apr; 32(4):301-11. PubMed ID: 25759210
[TBL] [Abstract][Full Text] [Related]
5. MTBP promotes migration and invasion by regulation of ZEB2-mediated epithelial-mesenchymal transition in lung cancer cells.
Pan B; Han H; Wu L; Xiong Y; Zhang J; Dong B; Yang Y; Chen J
Onco Targets Ther; 2018; 11():6741-6756. PubMed ID: 30349307
[TBL] [Abstract][Full Text] [Related]
6. MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4.
Agarwal N; Adhikari AS; Iyer SV; Hekmatdoost K; Welch DR; Iwakuma T
Oncogene; 2013 Jan; 32(4):462-70. PubMed ID: 22370640
[TBL] [Abstract][Full Text] [Related]
7. Reduced angiomotin p130 expression correlates with poor prognosis in lung adenocarcinoma.
Jang SH; Cho HD; Lee JH; Lee HJ; Hong SA; Cho J; Kim HJ; Oh MH
J Clin Pathol; 2017 Jul; 70(7):625-630. PubMed ID: 27980054
[TBL] [Abstract][Full Text] [Related]
8. MTBP Promotes the Invasion and Metastasis of Hepatocellular Carcinoma by Enhancing the MDM2-Mediated Degradation of E-Cadherin.
Lu S; Zhou W; Wei H; He L; Li L
Dig Dis Sci; 2015 Dec; 60(12):3681-90. PubMed ID: 26280083
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.
Grieb BC; Gramling MW; Arrate MP; Chen X; Beauparlant SL; Haines DS; Xiao H; Eischen CM
Cancer Res; 2014 Jul; 74(13):3591-602. PubMed ID: 24786788
[TBL] [Abstract][Full Text] [Related]
10. MDM2 binding protein as a predictor of metastasis and a novel prognostic biomarker in patients with gastric cancer.
Wang W; Chen Z; Jin J; Long Z; Liu X; Cai H; Zhou Y; Huang H; Wang Y
Oncol Lett; 2017 Dec; 14(6):6409-6416. PubMed ID: 29422956
[TBL] [Abstract][Full Text] [Related]
11. NOD2 maybe a biomarker for the survival of kidney cancer patients.
Xu D; Zhang S; Zhang S; Liu H; Li P; Yu L; Shang H; Hou Y; Tian Y
Oncotarget; 2017 Nov; 8(60):101489-101499. PubMed ID: 29254180
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between expression of long non-coding RNA ZXF1 and prognosis of lung adenocarcinoma and its potential molecular mechanism].
Pan GF; Zhou XF; Zhao JP
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):102-108. PubMed ID: 28219204
[No Abstract] [Full Text] [Related]
13. YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma.
Guo T; Zhao S; Wang P; Xue X; Zhang Y; Yang M; Li N; Li Z; Xu L; Jiang L; Zhao L; Ma PC; Rosell R; Li J; Gu C
Oncotarget; 2017 Jul; 8(29):48110-48125. PubMed ID: 28624808
[TBL] [Abstract][Full Text] [Related]
14. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis.
Odvody J; Vincent T; Arrate MP; Grieb B; Wang S; Garriga J; Lozano G; Iwakuma T; Haines DS; Eischen CM
Oncogene; 2010 Jun; 29(22):3287-96. PubMed ID: 20305689
[TBL] [Abstract][Full Text] [Related]
15. Mtbp haploinsufficiency in mice increases tumor metastasis.
Iwakuma T; Tochigi Y; Van Pelt CS; Caldwell LC; Terzian T; Parant JM; Chau GP; Koch JG; Eischen CM; Lozano G
Oncogene; 2008 Mar; 27(13):1813-20. PubMed ID: 17906694
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival.
Satoh N; Maniwa Y; Bermudez VP; Nishimura K; Nishio W; Yoshimura M; Okita Y; Ohbayashi C; Hurwitz J; Hayashi Y
Cancer Sci; 2011 May; 102(5):1101-6. PubMed ID: 21281403
[TBL] [Abstract][Full Text] [Related]
17. Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.
Inamura K; Yokouchi Y; Sakakibara R; Kobayashi M; Subat S; Ninomiya H; Nagano H; Nomura K; Okumura S; Ishikawa Y
Jpn J Clin Oncol; 2016 Oct; 46(10):935-941. PubMed ID: 27511990
[TBL] [Abstract][Full Text] [Related]
18. [Expression of glypican-3 in lung squamous cell carcinoma and adenocarcinoma and its relation with prognosis].
Li H; Deng Q; Huang L; Tang H; Cheng X
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):212-5. PubMed ID: 23443774
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological significance of Lgr5 expression in lung adenocarcinoma.
Ryuge S; Sato Y; Jiang SX; Wang G; Kobayashi M; Nagashio R; Katono K; Iyoda A; Satoh Y; Masuda N
Lung Cancer; 2013 Oct; 82(1):143-8. PubMed ID: 23915911
[TBL] [Abstract][Full Text] [Related]
20. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Jiang H; Wang H; Wang S; Pei Z; Fu Z; Fang C; Wang J; Lu Q; Wang E; Li J
Mol Med Rep; 2015 May; 11(5):3523-32. PubMed ID: 25573098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
